Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
Propanc Biopharma (OTC Pink: PPCB) announced significant interest in their scientific publications on proenzymes cancer treatment. Two peer-reviewed articles reached 10 citations and 4,500 reads in August 2024. The first article, published in Scientific Reports, demonstrates the effectiveness of proenzymes in suppressing pancreatic Cancer Stem Cells. The second article highlights the anti-tumor efficacy of pancreatic proenzymes, particularly for pancreatic and ovarian cancers.
A clinical study led by Dr. Kenyon showed that 41.3% of late-stage cancer patients treated with proenzymes had significantly longer survival times than expected. With global market projections for pancreatic cancer drugs at $6.93 billion by 2030 and ovarian cancer drugs at $13.9 billion by 2029, Propanc Biopharma aims to advance its lead asset, PRP, into early-stage clinical development to address the pressing need for new therapies with fewer side effects.
Propanc Biopharma (OTC Pink: PPCB) ha annunciato un notevole interesse per le loro pubblicazioni scientifiche sul trattamento del cancro con proenzimi. Due articoli sottoposti a revisione paritaria hanno raggiunto 10 citazioni e 4.500 letture nell'agosto 2024. Il primo articolo, pubblicato su Scientific Reports, dimostra l'efficacia dei proenzimi nell'inibire le cellule staminali cancerose del pancreas. Il secondo articolo evidenzia l'efficacia anti-tumorale dei proenzimi pancreatici, in particolare per i tumori pancreatici e ovarici.
Uno studio clinico condotto dal Dr. Kenyon ha mostrato che il 41,3% dei pazienti con cancro in stadio avanzato trattati con proenzimi ha avuto tempi di sopravvivenza significativamente più lunghi rispetto alle aspettative. Con le proiezioni di mercato globale per i farmaci contro il cancro del pancreas che raggiungeranno i 6,93 miliardi di dollari entro il 2030 e i farmaci contro il cancro ovarico che saliranno a 13,9 miliardi di dollari entro il 2029, Propanc Biopharma mira a portare il suo principale asset, PRP, nello sviluppo clinico nella fase iniziale per affrontare l’urgenza di nuove terapie con meno effetti collaterali.
Propanc Biopharma (OTC Pink: PPCB) anunció un interés significativo en sus publicaciones científicas sobre el tratamiento del cáncer con proenzimas. Dos artículos revisados por pares alcanzaron 10 citas y 4,500 lecturas en agosto de 2024. El primer artículo, publicado en Scientific Reports, demuestra la efectividad de las proenzimas en la supresión de las células madre cancerosas pancreáticas. El segundo artículo destaca la eficacia anti-tumoral de las proenzimas pancreáticas, especialmente para los cánceres de páncreas y ovario.
Un estudio clínico dirigido por el Dr. Kenyon mostró que el 41.3% de los pacientes con cáncer en etapa avanzada tratados con proenzimas tuvieron tiempos de supervivencia significativamente más largos de lo esperado. Con las proyecciones del mercado global para los medicamentos contra el cáncer de páncreas alcanzando los 6.93 mil millones de dólares para 2030 y los medicamentos contra el cáncer de ovario alcanzando los 13.9 mil millones de dólares para 2029, Propanc Biopharma tiene como objetivo avanzar su activo principal, PRP, a la fase temprana del desarrollo clínico para abordar la necesidad urgente de nuevas terapias con menos efectos secundarios.
프로팡크 바이오파마 (OTC 핑크: PPCB)는 프로엔자임을 이용한 암 치료에 관한 과학 연구 발표에 상당한 관심이 있다고 발표했습니다. 2024년 8월에 두 개의 동료 검토된 논문이 10회의 인용과 4,500회의 조회수를 기록했습니다. 첫 번째 논문은 Scientific Reports에 발표되어 프로엔자임이 췌장암 줄기세포를 억제하는 데 효과적임을 보여줍니다. 두 번째 논문은 췌장 및 난소암에 대한 췌장 프로엔자임의 항종양 효능을 강조합니다.
켄연 박사가 이끄는 임상 연구에서는 프로엔자임으로 치료받은 말기 암 환자의 41.3%가 예상보다 훨씬 긴 생존 시간을 가졌습니다. 췌장암 약물의 전 세계 시장 전망이 2030년까지 69억 3천만 달러에 이를 것으로 예상되며, 난소암 약물은 2029년까지 139억 달러에 이를 것으로 보이는 가운데, 프로팡크 바이오파마는 새로운 부작용이 적은 치료법의 긴급한 필요성을 해결하기 위해 PRP라는 주요 자산을 초기 임상 개발로 advancing 할 계획입니다.
Propanc Biopharma (OTC Pink: PPCB) a annoncé un intérêt significatif pour ses publications scientifiques sur le traitement du cancer par proenzymes. Deux articles évalués par des pairs ont atteint 10 citations et 4 500 lectures en août 2024. Le premier article, publié dans Scientific Reports, démontre l'efficacité des proenzymes dans la suppression des cellules souches cancéreuses du pancréas. Le second article met en lumière l'efficacité anti-tumorale des proenzymes pancréatiques, en particulier pour les cancers du pancréas et des ovaires.
Une étude clinique dirigée par le Dr. Kenyon a montré que 41,3% des patients atteints de cancer à un stade avancé traités avec des proenzymes ont eu des temps de survie nettement plus longs que prévu. Avec des prévisions de marché mondial pour les médicaments contre le cancer du pancréas s'élevant à 6,93 milliards de dollars d'ici 2030 et à 13,9 milliards de dollars pour les médicaments contre le cancer des ovaires d'ici 2029, Propanc Biopharma vise à avancer son actif principal, PRP, vers le développement clinique précoce afin de répondre à l'urgence d'une nouvelle thérapie avec moins d'effets secondaires.
Propanc Biopharma (OTC Pink: PPCB) gab bekannt, dass es ein erhebliches Interesse an seinen wissenschaftlichen Veröffentlichungen zur Behandlung von Krebs mit Proenzymen gibt. Zwei begutachtete Artikel erzielten im August 2024 10 Zitierungen und 4.500 Aufrufe. Der erste Artikel, veröffentlicht in Scientific Reports, zeigt die Wirksamkeit von Proenzymen bei der Suppression von Stammzellen des Bauchspeicheldrüsenkrebses. Der zweite Artikel hebt die anti-tumorale Wirksamkeit von Bauchspeicheldrüsenproenzymen hervor, insbesondere bei Bauchspeicheldrüsen- und Eierstockkrebs.
Eine klinische Studie unter der Leitung von Dr. Kenyon zeigte, dass 41,3% der Patienten mit fortgeschrittenem Krebs, die mit Proenzymen behandelt wurden, deutlich längere Überlebenszeiten hatten als erwartet. Mit globalen Marktprognosen für Medikamente gegen Bauchspeicheldrüsenkrebs von 6,93 Milliarden Dollar bis 2030 und 13,9 Milliarden Dollar für Eierstockkrebsmedikamente bis 2029 zielt Propanc Biopharma darauf ab, sein Hauptasset, PRP, in die frühe klinische Entwicklung zu bringen, um dem dringenden Bedarf an neuen Therapien mit weniger Nebenwirkungen zu begegnen.
- Two scientific publications reached 10 citations and 4,500 reads, indicating high interest in proenzymes cancer treatment
- Clinical study showed 41.3% of late-stage cancer patients treated with proenzymes had significantly longer survival times
- Mean survival of 9.0 months was significantly higher than mean life expectancy of 5.6 months in treated patients
- Global market for pancreatic cancer drugs projected to reach $6.93 billion by 2030
- Global market for ovarian cancer drugs projected to reach $13.9 billion by 2029
- Company's lead asset PRP is still in early-stage clinical development
- Current survival rates for pancreatic and ovarian cancers remain low at 20% and 29% respectively
Two Publications Reach 10 Citations & 4,500 Reads, Respectively
The first article, which reached 10 citations, published in Scientific Reports, is entitled, “Pancreatic proenzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting.” From the publishers of Nature, it is an online, open access journal, which publishes from all areas of the natural and clinical sciences. According to an insider, Scientific Reports is published on the most prestigious site of the National Institute of Health (NIH) and considered top line coverage: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684636/
Published data from the Company’s joint research and development program were generated in conjunction with the Universities of
The second article, achieved 4,500 reads, also published in Scientific Reports, entitled “A formulation of pancreatic proenzymes provides potent anti-tumor efficacy: A pilot study focused on pancreatic and ovarian cancer.” Published data from the Company's R&D program were conducted with vivoPharm Pty Ltd,
Additionally, clinical efficacy of a suppository formulation of pancreatic proenzymes in the context of a
For diagnosed pancreatic and ovarian cancer patients, there is a
“Survival rates, especially for pancreatic and ovarian cancers, continue to remain low. As a result, there is a pressing market need for new therapies, but without severe, or serious side effects associated with standard treatments,” said Dr Kenyon. “We look forward to advancing our lead asset, PRP, into early-stage clinical development to further improve the significant life extension I first observed using proenzymes treatment in the
About PRP:
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.
To view the Company’s “Mechanism of Action” video on the Company’s lead asset, PRP, please click on the following link: http://www.propanc.com/news-media/video.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the planned studies and market projections described above and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements because of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821711476/en/
Investor Relations and Media Contacts:
James Nathanielsz
Propanc Biopharma, Inc.
irteam@propanc.com
+61-3-9882-0780
Source: Propanc Biopharma, Inc.
FAQ
What milestone did Propanc Biopharma's (PPCB) scientific publications achieve in August 2024?
What were the results of the clinical study on proenzymes treatment for late-stage cancer patients?
What are the market projections for pancreatic and ovarian cancer drugs according to the Propanc Biopharma (PPCB) press release?
What is the current development stage of Propanc Biopharma's (PPCB) lead asset PRP?
